EPISODE · Apr 18, 2025 · 12 MIN
MPR Weekly Dose Podcast #233 — Pfizer ends development of weight loss drug; counterfeit Ozempic seized; daily pill demonstrates HbA1c reductions; mavacamten misses trial endpoint; smart belt to reduce fall injury
from MPR Weekly Dose
Pfizer ends danuglipron clinical program for obesity; FDA warns about counterfeit Ozempic; daily pill shows promise in reducing HbA1c; mavacamten misses in nonobstructive HCM trial and the FDA clears smart belt device reduce fall injury.
Embed this episode
Ready to play
MPR Weekly Dose Podcast #233 — Pfizer ends development of weight loss drug; counterfeit Ozempic seized; daily pill demonstrates HbA1c reductions; mavacamten misses trial endpoint; smart belt to reduce fall injury
0:00
12:36
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of MPR Weekly Dose?
This episode is 12 minutes long.
When was this MPR Weekly Dose episode published?
This episode was published on April 18, 2025.
Can I download this MPR Weekly Dose episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!